Lorenza Rimassa

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng et al. · New England Journal of Medicine · 2018 · 2.3K citations · Full text

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.3K citations · Full text

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Arndt Vogel, John Bridgewater, Julien Edeline et al. · Annals of Oncology · 2022 · 552 citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +12

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath et al. · The Lancet Oncology · 2012 · 549 citations

Second-line Treatment, Placebo-controlled Phase 2, Oncology +11